Leuprolide

Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.

🧴 Clinical Application

Administer by intramuscular (IM) or subcutaneous (SC) injection into the gluteus or abdomen once every 4 weeks (monthly depot). Must be reconstituted immediately before injection using the provided vehicle. In men with metastatic prostate cancer, co-administer an oral antiandrogen (e.g. bicalutamide) starting before leuprolide to prevent clinical symptoms of the initial testosterone surge.

⚠️ Side Effects

Common: Hot flashes/sweats, initial disease flare (transient increase in bone pain, urinary obstruction), erectile dysfunction, loss of libido, gynecomastia, fatigue, injection site pain. Rare/Severe: Spinal cord compression / ureteral obstruction during initial flare, pituitary apoplexy, QT prolongation, and osteoporosis.

🛡️ Safety Warnings

Black Box Warning: Initial tumor flare can cause fatal spinal cord compression, acute urinary obstruction, or bone pain in patients with vertebral metastases; co-administer antiandrogens for the first 2 to 4 weeks. Long-term therapy causes significant bone mineral loss; monitor bone density.